Axon Q2 2026: Record Revenue, AI Boom, and Raised Outlook Signal All-Clear on Operating Leverage

What happened

Axon delivered its 10th consecutive quarter of revenue growth above 30%, with Q2 revenue of $904 million rising 35% year-over-year, driven by 39% annual recurring revenue growth to $1.6 billion and net revenue retention of 126%. Software & Services climbed 36% to $398 million, AI Era revenue surged nearly 700%, and Platform Solutions jumped 123% to $150 million, while GAAP net income turned positive at $29 million. Adjusted EBITDA of $242 million delivered a 26.8% margin, well above the full-year guidance of 25.5% that management maintained even as it raised the revenue growth outlook to 32%–34%. The results directly contradict earlier concerns about tariff-driven margin compression and escalating stock-based compensation overwhelming profitability. With this print, the expansion flywheel shows it can absorb cost headwinds while scaling GAAP earnings, shifting the risk-reward more constructively.

Implication

Investors should see these results as evidence that Axon’s growth algorithm is strengthening, with GAAP profitability and adjusted EBITDA margin expansion proving the model can convert top-line momentum into bottom-line gains. The raised guidance and accelerating AI attach rate make the bull case more tangible. However, with the stock likely trading above the master report’s base-case implied value of $520, much of the good news is already priced in, and any deceleration would trigger severe multiple compression. The prudent approach is to wait for pullbacks toward the $440–$500 range for a more attractive entry, where the risk/reward tilts toward the bull case. In the meantime, the quarter justifies upgrading from a cautious WAIT to an accumulate-on-dips posture.

Thesis delta

The thesis shifts from waiting for tariff and SBC absorption to guarded optimism. Q2’s NRR of 126% and raised guidance decisively satisfy the prior requirement for sustained expansion, while GAAP profitability and AI segment breakout neutralize the core fear of operating leverage failure. Though valuation remains elevated, the accelerating platform story now supports a buy-on-weakness stance, upgrading the rating from WAIT.